On May 17, 2019, the European Medicines Agency (EMA) announced an important recommendation concerning Xeljanz (tofacitinib). Due to concerns about blood clots in the lungs, doctors shouldn't prescribe the twice...

On May 17, 2019, the European Medicines Agency (EMA) announced an important recommendation concerning Xeljanz (tofacitinib). Due to concerns about blood clots in the lungs, doctors shouldn't prescribe the twice...
As if the Intuitive Surgical wasn’t facing enough problems with its da Vinci Surgical Robot, the U.S. Food and Drug Administration (FDA) announced that the mechanical arms on some of the da Vinci robots could stall during robotic surgery, which...
(June 9, 2012) The U.S. Food and Drug Administration (FDA) approved a new anti-HER2 therapy, called Perjeta (pertuzumab) to treat patients with HER2-positive late-stage (metastatic) breast cancer. Perjeta is combined with...